Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

A. Awada, J. P. Delord, N. Houede, C. Lebbe, T. Lesimple, J. H. M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Article number604
Pages (from-to)185-186
Number of pages2
JournalEuropean Journal of Cancer
Publication statusPublished - Nov 2012
Externally publishedYes
Event24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Dublin, Ireland
Duration: 6 Nov 20129 Nov 2012

Cite this